ITERUM THERAPEUTICS    Dublin, Ireland
iterumtx.com

SULOPENEM
PENEM Β-LACTAM ANTIBIOTIC

Direct-Acting Small Molecule Therapeutic
Sulopenem, which is being supported by CARB-X funding, is an antibiotic under study for the treatment of infections caused by multi-drug resistant bacteria in hospital and community settings. These include the most urgent drug-resistant antimicrobial threats defined by the US Centers for Disease Control. Sulopenem is highly effective against the pathogens most commonly associated with uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra-abdominal infections, including potent in-vitro activity against Enterobacteriaceae mutants of E. coli and K. pneumonia. If approved, sulopenem will be available as a tablet and an intravenous formulation. Clinical studies will focus on urinary tract and complicated intra-abdominal infections. With careful stewardship from medical professionals and appropriate use by patients, sulopenem could be effective in the treatment of infections in patients in the community and could be useful in the early discharge of patients from hospital.

Current Development Stage: Phase I

CARB-X Investment: Investment of up to $1.5m.

Initial CARB-X Investment Date: July 1, 2017

Graduation Date: March 31, 2019